Cyclo Therapeutics Inc (CYTH)
0.715
+0.02
(+2.29%)
USD |
NASDAQ |
Nov 22, 10:17
Cyclo Therapeutics Enterprise Value: 31.36M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 31.36M |
| November 20, 2024 | 31.64M |
| November 19, 2024 | 30.84M |
| November 18, 2024 | 31.96M |
| November 15, 2024 | 31.36M |
| November 14, 2024 | 28.93M |
| November 13, 2024 | 31.96M |
| November 12, 2024 | 32.54M |
| November 11, 2024 | 31.68M |
| November 08, 2024 | 32.51M |
| November 07, 2024 | 31.86M |
| November 06, 2024 | 32.65M |
| November 05, 2024 | 31.56M |
| November 04, 2024 | 32.25M |
| November 01, 2024 | 32.01M |
| October 31, 2024 | 32.77M |
| October 30, 2024 | 31.99M |
| October 29, 2024 | 32.83M |
| October 28, 2024 | 32.11M |
| October 25, 2024 | 32.68M |
| October 24, 2024 | 33.60M |
| October 23, 2024 | 32.83M |
| October 22, 2024 | 33.46M |
| October 21, 2024 | 34.55M |
| October 18, 2024 | 33.52M |
| Date | Value |
|---|---|
| October 17, 2024 | 33.83M |
| October 16, 2024 | 33.98M |
| October 15, 2024 | 32.83M |
| October 14, 2024 | 32.63M |
| October 11, 2024 | 33.52M |
| October 10, 2024 | 33.40M |
| October 09, 2024 | 32.68M |
| October 08, 2024 | 32.47M |
| October 07, 2024 | 32.82M |
| October 04, 2024 | 32.57M |
| October 03, 2024 | 31.70M |
| October 02, 2024 | 32.28M |
| October 01, 2024 | 33.40M |
| September 30, 2024 | 33.95M |
| September 27, 2024 | 22.25M |
| September 26, 2024 | 21.68M |
| September 25, 2024 | 21.30M |
| September 24, 2024 | 20.82M |
| September 23, 2024 | 21.59M |
| September 20, 2024 | 21.96M |
| September 19, 2024 | 21.24M |
| September 18, 2024 | 20.27M |
| September 17, 2024 | 20.24M |
| September 16, 2024 | 20.01M |
| September 13, 2024 | 20.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.768M
Minimum
Nov 22 2022
66.35M
Maximum
Mar 17 2021
23.88M
Average
22.44M
Median
May 22 2020
Enterprise Value Benchmarks
| Stryker Corp | 159.53B |
| Biogen Inc | 27.62B |
| Pfizer Inc | 199.35B |
| Pacira BioSciences Inc | 936.04M |
| Moderna Inc | 7.852B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.833M |
| Revenue (Quarterly) | 0.2338M |
| Total Expenses (Quarterly) | 8.523M |
| EPS Diluted (Quarterly) | -0.31 |
| Gross Profit Margin (Quarterly) | 92.81% |
| Profit Margin (Quarterly) | -3.78K% |
| Earnings Yield | -125.9% |
| Normalized Earnings Yield | -128.70 |